Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on NxStage Medical

Share:
Related NXTM
Medtronic Has Big Plans For This Device (And It Could Help 500,000 People Each Year)
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

In a report published Friday, Jefferies & Company reiterated its Buy rating on NxStage Medical (NASDAQ: NXTM), but lowered its price target from $21.00 to $16.00.

Jefferies noted, “NXTM posted a decent 3Q. Overall HHD grew 17% but US HHD growth again decelerated (+12%) and will remain in check under the current reimbursement environment. The company outlined an increasing number of pipeline opportunities and while achieving increased reimbursement will take time, the substantial long-term HHD opportunity supports our Buy rating.”

NxStage Medical closed on Thursday at $10.61.

Latest Ratings for NXTM

DateFirmActionFromTo
Feb 2015Canaccord GenuityMaintainsBuy
Sep 2014Canaccord GenuityMaintainsBuy
Mar 2014Wells FargoDowngradesMarket PerformUnderperform

View More Analyst Ratings for NXTM
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (NXTM)

Get Benzinga's Newsletters